Yes, donepezil can cause dizziness and fainting. Fainting, also called syncope, is less common but may signal that the medicine has slowed the heartbeat. These effects do not happen to everyone, and a trial percentage cannot predict one person's response. Still, lightheadedness or fainting deserves prompt attention, especially in someone with heart problems.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- How common are dizziness and fainting?
- Why can donepezil cause fainting?
- Do dose and timing matter?
- What does the broader evidence show?
- What should you do about symptoms?
How common are dizziness and fainting?
In pooled placebo-controlled trials involving people with mild-to-moderate Alzheimer's disease, 8% taking donepezil reported dizziness. The rate was 6% among those taking a placebo, according to the National Library of Medicine's April 2024 DailyMed label. Syncope occurred in 2% of people taking donepezil and 1% taking a placebo.
Put simply, the trials found about two additional reports of dizziness and one additional fainting episode per 100 treated participants compared with placebo. These averages help show the size of the observed difference, but they are not personal odds. The label cautions that clinical-trial rates may differ from those seen in routine care.
Why can donepezil cause fainting?
donepezil can affect the heart through vagal activity, which influences heart rate. This effect can slow the heartbeat or interfere with the heart's electrical signals, a problem called heart block. The DailyMed label reports syncopal episodes in patients both with and without known heart-conduction abnormalities.
Its FDA-approved patient information says slow heartbeat and fainting occur more often in people with heart problems. That means a person does not need a previously diagnosed conduction disorder to experience fainting. A known heart problem, however, makes this warning particularly relevant.
Do dose and timing matter?
Higher-dose treatment may be harder to tolerate for some people. In a trial comparing 23 mg with 10 mg in moderate-to-severe Alzheimer's disease, dizziness caused 1% of the 23-mg group to stop treatment, compared with 0% of the 10-mg group.
Most discontinuations caused by adverse reactions in the 23-mg group occurred during the first month. New dizziness after starting donepezil or changing the dose should therefore be reported with its timing and current dose. A useful note for the clinician can include:.
- When the dizziness or fainting began
- Whether it followed a dose change
- The current dose
- Whether the person has a known heart problem
- Whether the event involved lightheadedness or complete loss of consciousness
What does the broader evidence show?
The evidence is not perfectly uniform. A population study of older adults with dementia found more hospital visits for syncope among cholinesterase-inhibitor users than nonusers: 31.5 versus 18.6 per 1,000 person-years, with an adjusted hazard ratio of 1.76. However, the 2009 Archives of Internal Medicine study examined the drug class and did not isolate donepezil.
By contrast, a 2024 analysis of 60 randomized donepezil trials found no statistically significant increase in syncope. The Journal of the American Geriatrics Society meta-analysis had a mean follow-up of only 31 weeks, and its authors said longer-duration research was needed. Together, these findings support caution without proving that every fainting episode during treatment was caused by donepezil. Short trials may also be limited in their ability to clarify an uncommon event over longer treatment periods.
What should you do about symptoms?
The FDA-approved patient information instructs people who feel faint or lightheaded while taking donepezil to contact their clinician promptly. Report actual loss of consciousness clearly rather than describing it only as dizziness.
Do not treat the trial percentages as a reason to dismiss an individual episode. A clinician needs the symptom details, dose, timing, and heart history to judge whether donepezil could be involved.
